Product Description: CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1].
Applications: Cancer-Kinase/protease
Formula: C29H37N7O2S
References: [1]Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.
CAS Number: 2369981-71-3
Molecular Weight: 547.71
Compound Purity: 98.05
Research Area: Cancer
Solubility: DMSO : 62.5 mg/mL (ultrasonic)
Target: Apoptosis;CDK